2017
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study
Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. The Lancet Respiratory Medicine 2017, 5: 857-868. PMID: 28942086, PMCID: PMC5677538, DOI: 10.1016/s2213-2600(17)30349-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesFemaleGene Expression ProfilingGenetic MarkersGenetic TestingHumansIdiopathic Pulmonary FibrosisLeukocytes, MononuclearLinear ModelsMaleMiddle AgedOligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsVital CapacityConceptsIdiopathic pulmonary fibrosisTransplant-free survivalRisk profilePulmonary fibrosisAntifibrotic drugsPeripheral blood mononuclear cellsCox proportional hazards modelClinical prediction toolGroup of patientsBlood mononuclear cellsHigh-risk groupProportional hazards modelPulmonary Fibrosis FoundationPittsburgh cohortUntreated patientsCohort studyClinical courseIPF diagnosisBlood InstituteProspective studyVital capacityMononuclear cellsPeripheral bloodUS National InstitutesNational Heart
2016
Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis
Tzouvelekis A, Herazo‐Maya J, Slade M, Chu J, Deiuliis G, Ryu C, Li Q, Sakamoto K, Ibarra G, Pan H, Gulati M, Antin‐Ozerkis D, Herzog EL, Kaminski N. Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis. Respirology 2016, 22: 486-493. PMID: 27761978, PMCID: PMC5352520, DOI: 10.1111/resp.12920.Peer-Reviewed Original ResearchConceptsTransplant-free survivalIdiopathic pulmonary fibrosisMMP-7 concentrationsMatrix metalloproteinase-7IPF patientsCause mortalityPulmonary fibrosisHealthy controlsMultivariate Cox proportional hazards modelCox proportional hazards modelPulmonary function parametersVariable clinical courseBaseline pulmonary function parametersProportional hazards modelIPF biomarkersProgressive diseaseClinical coursePoor prognosisPrognostic valueVital capacityIndependent biomarkerLung capacityPrognostic thresholdPlasma concentrationsMortality risk
2013
Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis
Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, Feingold E, Juan-Guardela BM, Richards TJ, Lussier Y, Huang Y, Vij R, Lindell KO, Xue J, Gibson KF, Shapiro SD, Garcia JG, Kaminski N. Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis. Science Translational Medicine 2013, 5: 205ra136. PMID: 24089408, PMCID: PMC4175518, DOI: 10.1126/scitranslmed.3005964.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCD28 AntigensCD4 AntigensCluster AnalysisCohort StudiesGene Expression ProfilingHumansIdiopathic Pulmonary FibrosisLeukocytes, MononuclearOligonucleotide Array Sequence AnalysisReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionSignal TransductionTreatment OutcomeConceptsTransplant-free survivalIdiopathic pulmonary fibrosisPeripheral blood mononuclear cell gene expression profilesReplication cohortCell gene expression profilesPoor outcomePulmonary fibrosisQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionProportional hazards modelTranscription-polymerase chain reactionGene expression profilesPotential cellular sourcesT cell activationIPF patientsLung transplantationMicroarray cohortPatient ageOutcome biomarkerPatient groupVital capacityPolymerase chain reactionT cellsDiscovery cohortITK expression
2012
Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fibrosis
Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF. Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2012, 185: 67-76. PMID: 22016448, PMCID: PMC3262037, DOI: 10.1164/rccm.201101-0058oc.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCell Adhesion MoleculesCohort StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansIdiopathic Pulmonary FibrosisIntercellular Adhesion Molecule-1Interleukin-8MaleMatrix Metalloproteinase 1Matrix Metalloproteinase 7Matrix MetalloproteinasesPredictive Value of TestsProportional Hazards ModelsS100 ProteinsS100A12 ProteinSurvival AnalysisVascular Cell Adhesion Molecule-1ConceptsIdiopathic pulmonary fibrosisTransplant-free survivalPoor transplant-free survivalPoor progression-free survivalProgression-free survivalDerivation cohortIL-8ICAM-1MMP-7Overall survivalPulmonary fibrosisValidation cohortCox proportional hazards modelVascular cell adhesion moleculeAdhesion moleculesLethal lung diseaseBead-based multiplex assayPoor overall survivalRisk prediction scoreMultiplex bead-based immunoassayAssociation of biomarkersProportional hazards modelIntercellular adhesion moleculePrioritization of patientsPlasma proteins
2007
Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern
Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N. Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern. PLOS ONE 2007, 2: e482. PMID: 17534432, PMCID: PMC1868965, DOI: 10.1371/journal.pone.0000482.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisMonths of symptomsSubset of patientsRapid progressorsPulmonary fibrosisProgression of IPFBronchoalveolar lavage (BAL) cellular profileActive matrix metalloproteinase-9Kaplan-Meyer methodRapid progressor groupTime of diagnosisBeginning of symptomsEnd-stage diseaseAccelerated clinical courseMatrix metalloproteinase-9Proportional hazards modelMigration/proliferationAdenosine 2B receptorSmooth muscle cellsAlveolar epithelial cellsIPF patientsProgressor groupSlow progressorsClinical courseInsidious onset